Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Trial details
- Who runs it
- Queen Mary University of London
- Trial code
- NCT04943588
- Record updated
- 17 July 2026
- Original description
We will determine how best to manage the hepatitis C virus (HCV) epidemic in Pakistan by measuring effectiveness of Pakistan-government sponsored current therapies, emergence of viral resistance, consequences of infection (chiefly liver cancer) and through developing models, based on incidence data, determine the proportion of people who need curative treatment to eliminate HCV, and assess whether targeting can optimise this.Read full original descriptionShow less
We will determine how best to manage the hepatitis C virus (HCV) epidemic in Pakistan by measuring effectiveness of Pakistan-government sponsored current therapies, emergence of viral resistance, consequences of infection (chiefly liver cancer) and through developing models, based on incidence data, determine the proportion of people who need curative treatment to eliminate HCV, and assess whether targeting can optimise this.
Inclusion: Adults over 18yrs old; Willing to undergo hepatitis C testing; Able and willing to give informed consent; Willing to return in 12 months time for repeat testing; Resident in area and not planning to leave the region.
Exclusion: Clinically significant illness (other than HCV) or other major medical condition that may interfere with the subject's treatment, assessment or compliance with protocol; Unwilling to give consent; Unwilling or unable to undergo the necessary procedures; Co-morbidities limiting life expectancy to less than 12 months.